A systematic review of 62 studies identified eight peptide biomarkers and several multi-peptide classifiers that could detect chronic kidney disease earlier than current blood and urine tests.
8 single peptide biomarkers identifiedPlus multi-peptide classifiers like CKD273 (273 peptides) that could detect kidney disease before standard creatinine and albumin tests
What the researchers found
From a systematic search of 3,668 articles, 62 studies met inclusion criteria and identified eight established single peptide biomarkers plus several proteomic classifiers (including CKD273 and IgAN237) for chronic kidney disease. These urinary peptide biomarkers show potential to detect kidney disease earlier than the current standard tests — serum creatinine and urinary albumin — which have known blind spots in early-stage kidney impairment.
Proteomic classifiers that analyze patterns across hundreds of peptides simultaneously (like CKD273, which uses 273 urinary peptides) are emerging as the most promising approach for clinical implementation.
Why it matters
Chronic kidney disease affects hundreds of millions of people worldwide, and current diagnostic tests miss early-stage disease when intervention would be most effective. Urinary peptide biomarkers could detect kidney damage before irreversible loss of function occurs. This systematic review maps the landscape of what's available and what's closest to clinical use, providing a roadmap for the transition from creatinine-based diagnostics to precision peptide-based detection.
The numbers in context
3,668 articles screened · 62 studies included · 8 single peptide biomarkers · CKD273 (273-peptide classifier) · IgAN237 (237-peptide classifier) · 5-year literature window
How the study worked
PRISMA-compliant systematic review searching the Web of Science database (October 2022) for English-language, full-text, original human studies published within the last 5 years and cited at least 5 times per year. Three independent authors performed abstract and full-text analysis. Excluded: animal models, transplant studies, metabolite/miRNA/exosomal vesicle studies.
Who was studied
Human studies of urinary peptide and proteomic biomarkers across the spectrum of chronic kidney disease
What this study cannot tell us
Limited to the Web of Science database, potentially missing studies indexed only in other databases. The 5-times-per-year citation requirement may exclude newer but important studies. The field is rapidly evolving, and the October 2022 search cutoff means more recent discoveries are not captured. Clinical validation and regulatory approval for most biomarkers discussed remain incomplete.
How to read the evidence
Rated high because this is a PRISMA-compliant systematic review with rigorous methodology, three independent reviewers, and clear inclusion/exclusion criteria, covering 62 qualifying studies.
When this study was published
Published in 2023 with literature through October 2022. The field of urinary proteomics is advancing rapidly, so newer biomarker discoveries may have emerged since this review.
The bigger picture
Kidney disease is often called a 'silent killer' because it's usually advanced by the time standard tests catch it. The shift toward urinary peptidomics — scanning entire peptide profiles rather than single markers — represents a broader trend in precision diagnostics. If validated and adopted clinically, these tools could transform kidney disease from a late-diagnosis condition to one caught and managed early, potentially saving millions from dialysis or transplant.
Questions still open
- What regulatory hurdles remain before CKD273 or similar proteomic classifiers can be used in routine clinical practice?
- Could these urinary peptide panels also predict which kidney disease patients will progress to end-stage disease?
- How cost-effective would mass spectrometry-based urinary peptide testing be compared to current creatinine and albumin tests?
Common questions
Why aren't current kidney tests good enough?
What is CKD273 and how does it work?
Read the original research
Recent Advances in Urinary Peptide and Proteomic Biomarkers in Chronic Kidney Disease: A Systematic Review.
International journal of molecular sciences, 24(11)
Citation
Catanese, Lorenzo; Siwy, Justyna; Mischak, Harald; Wendt, Ralph; Beige, Joachim; Rupprecht, Harald. (2023). Recent Advances in Urinary Peptide and Proteomic Biomarkers in Chronic Kidney Disease: A Systematic Review.. International journal of molecular sciences, 24(11). https://doi.org/10.3390/ijms24119156